{"nct_id":"NCT06099782","title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-04","start_date":"2023-12-26","start_date_type":"ACTUAL","primary_completion_date":"2025-04-09","primary_completion_date_type":"ACTUAL","completion_date":"2026-11-16","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}